天演药业上涨8.98%，报1.82美元/股，总市值8577.89万美元

Core Viewpoint - Tianyan Pharmaceutical (ADAG) is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceutical reported total revenue of $103,200, representing a year-over-year decrease of 99.43% [1]. - The company recorded a net loss attributable to shareholders of $33.4241 million, a decline of 76.41% compared to the previous year [1]. Market Activity - On December 16, Tianyan Pharmaceutical's stock opened with an increase of 8.98%, reaching $1.82 per share by 22:30, with a total trading volume of $167,200 and a market capitalization of $85.577 million [1]. Company Overview - Tianyan Pharmaceutical is listed on NASDAQ under the ticker symbol ADAG and is dedicated to discovering and developing innovative cancer immunotherapies [1]. - The company's antibody discovery engine, known as the "Dynamic Precision Library," is driving the development of its product pipeline, aiming to create potentially global innovative or best-in-class products [1].